{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:48:26Z","timestamp":1788961706954,"version":"build-2803163510"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202738"],"award-info":[{"award-number":["82202738"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>In gliomas, various oncogenic factors can lead to an imbalance between cell proliferation and apoptosis. Lomustine inhibits tumor cell growth by disrupting DNA replication and repair mechanisms. In contrast, temozolomide, an imidazole tetrazine compound, promotes cell apoptosis through DNA alkylation. The present study aimed to systematically analyze and compare the adverse drug reactions (ADRs) associated with lomustine and temozolomide, as reported in the World Health Organization (WHO) VigiAcess database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Utilizing a retrospective descriptive analysis design, this study focused on two commercially available anti-glioma drugs. ADR reports pertaining to these medications were collected from the WHO-VigiAccess database. The data collection process involved gathering detailed information on various parameters, including age groups, gender, and geographical distribution of patients involved in the ADR reports. Additionally, the study examined the disease systems and symptoms reported alongside the adverse reactions, as recorded in the annual ADR summaries generated by the WHO. By calculating the proportion of adverse events reported for each drug, this investigation provided a comparative analysis of both the similarities and differences in the adverse reactions observed across the two anti-glioma drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At the time of the search, a total of 22,854 adverse events (AEs) associated with the two anti-glioma drugs were documented in the VigiAccess database. Lomustine exhibits a higher reporting rate concerning blood and lymphatic system disorders, gastrointestinal disorders, and hepatobiliary disorders. In contrast, Temozolomide has a higher reporting rate for general disorders and administration site conditions, nervous system disorders, and skin and subcutaneous tissue disorders. The top five types of AEs for anti-glioma drugs are as follows: general disorders and administration site conditions (8,825 cases, 38.61%), blood and lymphatic system disorders (7,369 cases, 32.24%), gastrointestinal disorders (5,614 cases, 24.56%), nervous system disorders (5,047 cases, 22.08%), and investigations (4,855 cases, 21.24%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The present comparative observational study indicates that these inhibitors are associated with both common and specific adverse reactions, as documented in ADR reports. Clinicians should formulate individualized treatment plans that consider the adverse reactions linked to various drugs and the specific conditions of each patient, thereby promoting the rational use of these costly medications.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1534802","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T06:51:33Z","timestamp":1741243893000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Adverse event profile of lomustine and temozolomide: a descriptive analysis from WHO-VigiAccess"],"prefix":"10.3389","volume":"16","author":[{"given":"Hua","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youfu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s10067-012-2040-2","article-title":"The effect of neutralizing antibodies on the sustainable efficacy of biologic therapies: what's in it for African and Middle Eastern rheumatologists","volume":"31","author":"Alawadhi","year":"2012","journal-title":"Clin. Rheumatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3346\/jkms.2014.29.7.980","article-title":"Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea","volume":"29","author":"Bae","year":"2014","journal-title":"J. Korean Med. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/14740338.2019.1630063","article-title":"Comparison of post-marketing surveillance approaches regarding infections related to tumor necrosis factor inhibitors (TNFi's) used in treatment of autoimmune diseases","volume":"18","author":"Chen","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s13311-017-0519-x","article-title":"Glioma subclassifications and their clinical significance","volume":"14","author":"Chen","year":"2017","journal-title":"Neurotherapeutics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1159\/000531319","article-title":"Glioblastoma multiforme: the latest diagnostics and treatment techniques","volume":"108","author":"Czarnywojtek","year":"2023","journal-title":"Pharmacology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.neo.2018.05.001","article-title":"Improved brain penetration and antitumor efficacy of temozolomide by inhibition of ABCB1 and ABCG2","volume":"20","author":"de Gooijer","year":"2018","journal-title":"Neoplasia"},{"key":"B7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case-non-case studies: principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapie"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.3390\/pharmaceutics14112328","article-title":"Real-world safety profile of biologics used in rheumatology: a six-year observational pharmacovigilance study in the calabria region","volume":"14","author":"Gagliardi","year":"2022","journal-title":"Pharmaceutics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.vaccine.2019.11.050","article-title":"Barriers to healthcare workers reporting adverse events following immunization in four regions of Ghana","volume":"38","author":"Gidudu","year":"2020","journal-title":"Vaccine"},{"key":"B10","doi-asserted-by":"publisher","first-page":"8276","DOI":"10.18632\/aging.202636","article-title":"Identification and validation of a two-gene metabolic signature for survival prediction in patients with kidney renal clear cell carcinoma","volume":"13","author":"Guo","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.semcancer.2017.11.010","article-title":"Glioma epigenetics: from subclassification to novel treatment options","volume":"51","author":"Gusyatiner","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/pds.5249","article-title":"Pharmacovigilance network as an additional tool for the surveillance of antimicrobial resistance","volume":"30","author":"Habarugira","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","journal-title":"Lancet"},{"key":"B15","article-title":"Glioblastoma multiforme","volume-title":"StatPearls","author":"Kanderi","year":"2024"},{"key":"B16","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/rheumatology\/kez609","article-title":"Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies","volume":"59","author":"Kvamme","year":"2020","journal-title":"Rheumatol. Oxf."},{"key":"B17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/s0921-8777(01)00105-7","article-title":"Repair of O(6)-methylguanine is not affected by thymine base pairing and the presence of MMR proteins","volume":"487","author":"Lips","year":"2001","journal-title":"Mutat. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00535-016-1266-1","article-title":"Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review","volume":"52","author":"Martelli","year":"2017","journal-title":"J. Gastroenterol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2176\/nmc.oa.2014-0413","article-title":"Profile analysis of chemotherapy-induced nausea and vomiting in patients treated with concomitant temozolomide and radiotherapy: results of a prospective study","volume":"55","author":"Matsuda","year":"2015","journal-title":"Neurol. Med. Chir. (Tokyo)"},{"key":"B21","volume-title":"Livertox: clinical and research information on drug-induced liver injury","year":"2012"},{"key":"B22","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2174\/1570159X18666200626204005","article-title":"Temozolomide: an updated overview of resistance mechanisms, nanotechnology advances and clinical applications","volume":"19","author":"Ortiz","year":"2021","journal-title":"Curr. Neuropharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/biomedicines7030069","article-title":"Temozolomide and other alkylating agents in glioblastoma therapy","volume":"7","author":"Strobel","year":"2019","journal-title":"Biomedicines"},{"key":"B24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3389\/fphar.2020.00315","article-title":"Intravitreal anti-VEGF drugs and signals of dementia and Parkinson-like events: analysis of the VigiBase database of spontaneous reports","volume":"11","author":"Sultana","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40264-019-00899-y","article-title":"Investigating overlap in signals from EVDAS, FAERS, and VigiBase\u00ae","volume":"43","author":"Vogel","year":"2020","journal-title":"Drug Saf."},{"key":"B26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40264-017-0594-2","article-title":"Safety concerns reported by patients identified in a collaborative signal detection workshop using VigiBase: results and reflections from lareb and uppsala monitoring centre","volume":"41","author":"Watson","year":"2018","journal-title":"Drug Saf."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2020.02.002","article-title":"Immunotherapy for glioma: current management and future application","volume":"476","author":"Xu","year":"2020","journal-title":"Cancer Lett."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2109365","DOI":"10.1080\/21645515.2022.2109365","article-title":"Adverse events following immunization associated with coronavirus disease 2019 (COVID-19) vaccines: a descriptive analysis from VigiAccess","volume":"18","author":"Yamoah","year":"2022","journal-title":"Hum. Vaccin Immunother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2174\/1874467211205010102","article-title":"Temozolomide: mechanisms of action, repair and resistance","volume":"5","author":"Zhang","year":"2012","journal-title":"Curr. Mol. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3892\/or.2022.8312","article-title":"Research progress of anti-glioma chemotherapeutic drugs (Review)","volume":"47","author":"Zhou","year":"2022","journal-title":"Oncol. Rep."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1534802\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T06:51:35Z","timestamp":1741243895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1534802\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":30,"alternative-id":["10.3389\/fphar.2025.1534802"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1534802","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"article-number":"1534802"}}